摘要
目的 探讨美托洛尔联合阿托伐他汀治疗心肌梗死的疗效。方法 142例心肌梗死患者,根据治疗方法不同分为观察组和对照组,每组71例。对照组患者使用硝酸异山梨酯片进行治疗,观察组患者使用美托洛尔联合阿托伐他汀进行治疗。对比两组患者的心功能指标[心输出量(CO)、左室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、二尖瓣口舒张早期血流速度峰值与舒张晚期血流速度峰值的比值(E/A)]、临床疗效、不良事件发生情况。结果 治疗前,两组患者的CO、LVEF、LVEDD、E/A比较差异均无统计学意义(P>0.05);治疗后,观察组患者的CO(4.54±0.91)L/min、LVEF(55.42±8.13)%、E/A(1.35±0.15)均高于对照组的(3.27±0.87)L/min、(44.16±8.42)%、(1.12±0.28),LVEDD(43.73±5.15)mm小于对照组的(54.19±5.23)mm,差异有统计学意义(P<0.05)。观察组患者的临床总有效率为92.96%,显著高于对照组的77.46%,差异有统计学意义(P<0.05)。观察组患者的不良事件发生率为7.04%,显著低于对照组的23.94%,差异有统计学意义(P<0.05)。结论 心肌梗死患者采用美托洛尔联合阿托伐他汀治疗,疗效显著,能显著改善患者的心功能,并降低了不良事件发生几率,值得临床推广。
Objective To discuss the efficacy of metoprolol combined with atorvastatin in the treatment of myocardial infarction.Methods A total of 142 patients with myocardial infarction were divided into observation group and control group according to different treatment methods,with 71 cases in each group.Patients in the control group were treated with isosorbide nitrate tablets,and patients in the observation group were treated with metoprolol combined with atorvastatin.Both groups were compared in terms of cardiac function index[cardiac output(CO),left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),early diastolic peak flow velocity of mitral valve/late diastolic peak flow velocity of mitral valve(E/A)],clinical efficacy,and occurrence of adverse events.Results Before treatment,there was no statistically significant difference in CO,LVEF,LVEDD and E/A between the two groups(P>0.05).After treatment,the CO(4.54±0.91)L/min,LVEF(55.42±8.13)%and E/A(1.35±0.15)of the observation group were higher than(3.27±0.87)L/min,(44.16±8.42)%and(1.12±0.28)of the control group;the LVEDD(43.73±5.15)mm of the observation group was smaller than(54.19±5.23)mm of the control group;the differences were all statistically significant(P<0.05).The total clinical effective rate in the observation group was 92.96%,which was significantly higher than 77.46%in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse events in the observation group was 7.04%,which was significantly lower than 23.94%in the control group,and the difference was statistically significant(P<0.05).Conclusion Metoprolol combined with atorvastatin has a significant efficacy for patients with myocardial infarction,and can significantly improve the patient’s cardiac function,and reduce the incidence of adverse events,which is worthy of clinical promotion.
作者
饶飞龙
RAO Fei-long(Zhuhai Fifth People's Hospital,Zhuhai 519055,China)
出处
《中国实用医药》
2022年第25期131-134,共4页
China Practical Medicine
关键词
美托洛尔
阿托伐他汀
心肌梗死
Metoprolol
Atorvastatin
Myocardial infarction
